BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 18025271)

  • 1. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
    Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
    Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
    Le XF; Pruefer F; Bast RC
    Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
    Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.
    García-Morales P; Hernando E; Carrasco-García E; Menéndez-Gutierrez MP; Saceda M; Martínez-Lacaci I
    Mol Cancer Ther; 2006 Sep; 5(9):2172-81. PubMed ID: 16985050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.
    Good DW; George T; Watts BA
    J Biol Chem; 2008 Sep; 283(39):26602-11. PubMed ID: 18660503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts.
    Takai S; Tokuda H; Hanai Y; Harada A; Yasuda E; Matsushima-Nishiwaki R; Kato H; Ogura S; Ohta T; Kozawa O
    J Bone Miner Res; 2007 Mar; 22(3):337-46. PubMed ID: 17181399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.
    Yoon S; Lee MY; Park SW; Moon JS; Koh YK; Ahn YH; Park BW; Kim KS
    J Biol Chem; 2007 Sep; 282(36):26122-31. PubMed ID: 17631500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
    Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation.
    Wing LY; Chen HM; Chuang PC; Wu MH; Tsai SJ
    J Biol Chem; 2005 May; 280(20):19937-47. PubMed ID: 15760907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
    Miller TW; Forbes JT; Shah C; Wyatt SK; Manning HC; Olivares MG; Sanchez V; Dugger TC; de Matos Granja N; Narasanna A; Cook RS; Kennedy JP; Lindsley CW; Arteaga CL
    Clin Cancer Res; 2009 Dec; 15(23):7266-76. PubMed ID: 19934303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.